A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease

NCT06388083 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

STGD1
Stargardt Disease 1

Interventions

DRUG: Tinlarebant
DRUG: Placebo

Sponsor

Belite Bio, Inc